Table 3: Baseline characteristics and treatment response in 37 patients treated with peginterferon, ribavirin, and telaprevir according to IFNL4 ss469415590 variant.

IFNL4 major, IFNL4 minor, values (major versus minor groups)

Gender, male/female19/59/40.78
Age, years59.5 ± 7.755.2 ± 10.20.15
Previous treatment: naïve/relapse/null10/13/17/4/20.71
AST, IU/L50.9 ± 48.959.8 ± 44.20.58
ALT, IU/L63.8 ± 60.577.9 ± 77.20.54
γ-GTP, IU/L51.8 ± 52.278.6 ± 73.30.25
Hemoglobin, g/dL14.6 ± 1.214.5 ± 1.30.81
Platelets, ×104/mm315.9 ± 5.216.5 ± 5.30.74
HCV RNA ()6.70 ± 0.546.18 ± 0.870.0309
Treatment response
 RVR, 1780.83
 EVR, 22100.45
 SVR/relapse/null2280.0727

Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.